EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment

Peter Batar, Gabriella Mezei, Arpad Illes

Current Oncology · 2025

DOI: 10.3390/curroncol32020097 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2025. Verfasst von Peter Batar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Institute of Internal Medicine, Clinical Center, University of Debrecen, H-4002 Debrecen, Hungary. Hauptthemen laut MEDLINE: Antineoplastic Agents, Dasatinib, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the groundbreaking success of tyrosine kinase inhibitor therapy, the management of chronic myeloid leukemia patients is often impaired by resistance due to specific point mutations in the BCR::ABL1 oncogene. Upon classical ATP-competitive inhibitor treatment, these single nucleotide variants occur in the tyrosine kinase domain of ABL1. The novel allosteric BCR::ABL1 inhibitor asciminib was developed to treat CML patients alone or in combination to overcome or potentially prevent these treatment-emergent TKD mutations. Here, we present a case of a patient undergoing first-line asciminib therapy, and subsequently develop a specific BCR::ABL1/A337V point mutation, which resulted in asciminib resistance. Switching to second-line dasatinib treatment successfully overcame asciminib resistance and helped to achieve a deep molecular response. In case of treatment failures caused by single asciminib-specific point mutations, dasatinib therapy is a feasible choice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDasatinibDrug Resistance, NeoplasmFusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsPyrazolesHumansMutationPoint MutationProto-Oncogene Proteins c-ablNiacinamide

Stichwörter der Autor:innen

TKI resistanceallosteric inhibitorchronic myeloid leukemiasingle nucleotide varianttyrosine kinase inhibitor

Substanzen

Antineoplastic AgentsasciminibDasatinibFusion Proteins, bcr-ablProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazolesNiacinamide

Autor:innen und Institutionen

  • Division of Hematology, Institute of Internal Medicine, Clinical Center, University of Debrecen, H-4002 Debrecen, Hungary.
  • Department of Hematology, Faculty of Medicine, Doctoral School of Clinical Sciences, University of Debrecen, H-4002 Debrecen, Hungary.

Zitieren

APA

Batar, P., Mezei, G., & Illes, A. (2025). Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment. Current Oncology. https://doi.org/10.3390/curroncol32020097

Vancouver

Batar P, Mezei G, Illes A. Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment. Current Oncology. 2025. doi:10.3390/curroncol32020097

BibTeX
@article{Batar2025,
  author = {Batar, Peter and Mezei, Gabriella and Illes, Arpad},
  title = {Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32020097}
}
Kostenlos starten →